In addition, there are several other factors that are driving the market to grow such as the initiative taken by the government, rising awareness within individuals related to carcinogenic effects of smoking. Different nations imply different fines on smoking in public places. New combine therapies are being utilized for the treatment of the lung cancer. The market is also driven by the increase in the number of smokers globally. As per the Tobacco Atlas organization, in the year 2014, 5.8 trillion cigarettes were smoked globally. There are several different factors that tends to drive the market such as rising pollution due to urbanization, changing lifestyle, increasing number of lung cancer patients, and technological developments such as utilization of biomarkers for recognition of lung cancer.
North America and Europe has a considerable contribution to the growth of global lung cancer therapeutics market followed by APAC region. The key driving forces include rising incidence of lung cancer diseases and adoption of lung cancer drugs and surgeries across the globe. Emerging economies such as China, India, Japan, and Korea have most lung cancer patients and with improved healthcare system and healthcare spending APAC region looks promising for global lung cancer therapeutics market. Improved standard of living, infrastructural development and favorable government policies are some other factors that will boost the APAC market. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, pipeline analysis, patent analysis, strategic recommendations, key company analysis, key findings, analyst insights and predictive analysis of the market.
The global lung cancer therapeutics market companies include Boehringer Ingelheim, Abbvie, Eli Lilly, F. Hoffmann-La Roche GlaxoSmithKline, Merck Serono and Novartis. Lung cancer therapeutics companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
Global lung cancer therapeutics market by drugs includes Platinol, Taxol, Gemzar, Alimta, Iressa, Hycamtin, Gilotrif, Taxotere, Xalkori, Navelbine, Avastin, Tarceva and Others.
Global lung cancer therapeutics market by therapy include chemotherapy, targeted therapy, immunotherapy, radiation therapy, others.
Global lung cancer therapeutics market by end-user includes multi-speciality hospitals and cancer research centres.
The Report Covers:
Comprehensive research methodology of global lung cancer therapeutics market.
This report also includes detailed and extensive market overview with historical analysis & key analyst’s insights.
An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global lung cancer therapeutics market.
Insights about market determinants which are stimulating the global lung cancer therapeutics market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
1.2.3. By Stakeholders
2. Market Overview and Insights
2.2. Analyst Insight
2.2.1. Key Findings & Current Market Trends
2.3.1. United States
2.3.2. European Union
2.3.5. Rest of the World
2.4. Pipeline Analysis
2.4.1. Keytruda Mk-3475 Non-Small Cell Lung Cancer Drug
2.4.2. Atezolizumab (Anti-Pdl1, Rg7446, Mpdl3280A) Roche
2.4.3. Rg6016 (Roche)
2.4.4. Trastuzumab Emtansine (T-Dm1)
2.4.5. Rg7604 Pik3Ca
2.4.6. Alectinib (Rg7853)
2.5. Newly Approved Drugs
2.5.1. Alecensa (Alectinib), Roche
2.5.2. Keytruda (Pembrolizumab), Merck
2.5.3. Opdivo (Nivolumab), Bristol-Myers Squibb
2.5.4. Portrazza (Necitumumab), Eli Lilly
2.5.5. Tagrisso (Osimertinib), Astrazeneca
2.5.6. Abitrexate (Methotrexate)
2.5.7. Avastin (Bevacizumab)
2.5.9. Folex (Methotrexate)
3. Market Determinant
3.1.1. Rise In Incidence & Prevalence Rate of Cancer Diseases
3.1.2. Rise In Investment and Grants From Government and Private Players
3.1.3. Growth In Pharmaceutical Market of Lung Cancer
3.1.4. Adoption of Innovative Lung Surgery
3.1.5. Regulatory Approvals To Lung Cancer Drugs
3.2.1. High Cost of Global Lung Cancer Drugs and Surgeries
3.2.2. Reimbursement Policies May Affect the Growth of the Market
3.3.1. Apac Region Have Huge Opportunity For Global Lung Cancer Market
3.3.2. Successful Clinical Trials
4. Market Segmentation
4.1. Lung Cancer Therapeutics Market By Drugs
4.2. Global Lung Cancer Therapeutics Market, By Therapy
4.2.2. Targeted Therapy
4.2.4. Radiation Therapy
4.3. Global Lung Cancer Therapeutics Market, By End User
4.3.1. Multispeciality Hospitals
4.3.2. Cancer Research Centers
5. Competitive Landscape
5.1. Market Share Analysis
5.2. Key Company Analysis
6. Regional Analysis
6.1. North American
6.1.1. United States
6.3. Asia Pacific
6.4. Rest of the World
7. Company Profiles
7.5. Boehringer Ingelheim
7.9. Eli Lilly
7.10. F. Hoffmann-La Roche
7.14. Merck Serono
7.17. Osi Pharmaceuticals
7.19. Pfizer, Inc.
7.20. Pierre Fabre
7.25. Teva Pharmaceutical
- Boehringer Ingelheim
- Eli Lilly
- F. Hoffmann-La Roche
- Merck Serono
- Osi Pharmaceuticals
- Pfizer, Inc.
- Pierre Fabre
- Teva Pharmaceutical